BATON ROUGE, LA--(Marketwired - October 09, 2015) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) (the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to announce that Dr. Jonathan Head presented interim data on the Company's Phase 1 clinical trial of the novel vaccine ProscaVax for prostate cancer.

The Phase 1 trial, expected to be completed in December, is investigating the safety and efficacy of ProscaVax, while evaluating the effects of the vaccine on survivability, time to measurable disease, prostate-specific antigen (PSA) level in the blood, and the immune response to ProscaVax. PSA, a protein produced by the prostate gland, is commonly elevated in prostate cancer patients and closely monitored as a measure of disease progression in men diagnosed with prostate cancer.

More information on the trial is available on the website at:

The presentation, titled "A Phase 1 clinical trial of a therapeutic prostate cancer vaccine containing PSA/IL-2/GM-CSF in PSA defined biochemical recurrent prostate cancer patients," was at the CRI-CIMT-EATI-AACR: Inaugural International Cancer Immunotherapy Conference: Translating Science Into Survival meeting in New York City on October 16, 2015. The newly released data supports an increase in immunity to the PSA antigen post-vaccine and a decrease in PSA progression rate in patients previously treated with standard therapies with biochemical failure.

"Years of research and clinical data support the safety and benefit of ProscaVax as an immunotherapy in prostate cancer patients," commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune. "This most recent poster lends further validation to our work and the potential for ProscaVax as we prepare to move into a Phase 2 clinical trial."

The presentation is available for viewing at:

About OncBioMune Pharmaceuticals

OncBioMune Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a proprietary Vaccine Technology that is designed to stimulate the immune system to attack its own cancer while not hurting the patient. Our lead product, ProscaVax(r) is scheduled to commence a Phase 2 clinical study in early 2016. OncBioMune also has a portfolio of targeted therapies, some of which are biosimilars to blockbuster drugs. OncBioMune is headquartered in Baton Rouge, LA.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause OncBioMune Pharmaceutical's actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. OncBioMune Pharmaceuticals has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are OncBioMune Pharmaceuticals' need for, and the availability of, substantial capital in the future to fund its operations and research and development; the fact that OncBioMune Pharmaceutical's vaccines and therapeutics may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in OncBioMune Pharmaceutical's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. OncBioMune Pharmaceuticals undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

Contact Information:

OncBioMune Pharmaceuticals
Andrew Kucharchuk
President and Chief Financial Officer